GA_P advises Oryzon on €20m capital rise
Gómez-Acebo & Pombo has advised Spanish biopharmaceutical company Oryzon Genomics on a capital increase of €20 million
The company has announced a capital increase of new common shares for an aggregate amount of €20 million. The capital increase was carried out through a private placement. Oryzon intends to use the capital increase to finance the company’s research and development of clinical pipeline candidates, continue with the preparations for a potential dual listing on Nasdaq in the future and other general corporate purposes.
Subject to completion of certain customary closing procedures, the admission of the new shares to trading on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, through the Spanish Automated Quotation System is expected on June 26, 2020.
Jefferies International was Sole Global Coordinator and Joint Bookrunner, Kempen & Co was Joint Bookrunner, and Andbank España, S.A.U. was Co-Manager in the Capital Increase. Gómez-Acebo & Pombo, (Oryzon’s Spanish counsel) and Davis Polk & Wardwell (their U.S. and English counsel) have acted as legal advisers to the company, and White & Case has acted as Spanish, English and U.S. legal adviser to the Placement Agents.
Gómez-Acebo & Pombo´s team was led by Madrid office partner Augusto Piñel (pictured left), assited by lawyers Jacobo Palanca (pictured centre) and Íñigo Hernáez (pictured right).